Dr. Anne Tsao, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Texas Md Anderson Cancer Center

  Fellowship Hospital, 2004

• Indiana University

  Residency Hospital, 2001

• University Of Chicago Pritzker School Of Medicine

  Medical School, 1998

• Poziotinib forEGFRexon 20 mutant NSCLC: clinical efficacy, resistance mechanisms and impact of insertion location on drug sensitivity, 2022-07-11

• Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations, 2023-08-11

• Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer, 2022-01-07

• Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations, 2022-04-21

• Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC), 2010-06-29

• Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial, 2016-10-27

• Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study, 2016-10-24

• Phase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905), 2017-06-06

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021-02-18

• Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues, 2021-02-25

• Case Report: Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients with Lung Adenocarcinoma, 2015-11-17

• Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer, 2022-01-23

• A practical guide of the Southwest Oncology Group (SWOG) to measure malignant pleural mesothelioma (MPM) tumors by RECIST and modified RECIST criteria, 2011-03-11

• Patterns of Failure, Toxicity, and Survival after Extrapleural Pneumonectomy and Hemithoracic Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma, 2017-09-06

• Integrative Molecular Characterization of Malignant Pleural Mesothelioma, 2018-10-15

• Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-ß) is associated withPDGFRBgene copy number gain in sarcomatoid non-small cell lung cancer (NSCLC), 2011-05-17

• Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer WithEGFRExon 20 Insertion Mutations From a Phase 1/2 Trial, 2021-02-25

• Non-Small Cell Lung Cancer withHER2Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment, 2012-12-29

• A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma, 2017-09-28

• Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial, 2016-11-14

• A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners, 2018-01-24

• Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners, 2016-04-27

• ElevatedPDGFRBgene copy number gain (CNG) is prognostic for improved survival outcomes in resected malignant pleural mesothelioma, 2014-02-20

• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial, 2023-03-16